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Abstract
In recent years, several entry mediators have been characterized for porcine reproductive and respiratory syndrome virus
(PRRSV). Porcine sialoadhesin [pSn, also known as sialic acid-binding immunoglobulin-type lectin (Siglec-1)] and porcine
CD163 (pCD163) have been identified as the most important host entry mediators that can fully coordinate PRRSV infection
into macrophages. However, recent isolates have not only shown a tropism for sialoadhesin-positive cells, but also for
sialoadhesin-negative cells. This observation might be partly explained by the existence of additional receptors that can
support PRRSV binding and entry. In the search for new receptors, recently identified porcine Siglecs (Siglec-3, Siglec-5 and
Siglec-10), members of the same family as sialoadhesin, were cloned and characterized. Only Siglec-10 was able to
significantly improve PRRSV infection and production in a CD163-transfected cell line. Compared with sialoadhesin, Siglec-10
performed equally effectively as a receptor for PRRSV type 2 strain MN-184, but it was less capable of supporting infection
with PRRSV type 1 strain LV (Lelystad virus). Siglec-10 was demonstrated to be involved in the endocytosis of PRRSV,
confirming the important role of Siglec-10 in the entry process of PRRSV. In conclusion, it can be stated that PRRSV may use
several Siglecs to enter macrophages, which may explain the strain differences in the pathogenesis.
INTRODUCTION
Porcine reproductive and respiratory syndrome (PRRS) is
one of the most economically devastating diseases in the pig
industry [1]. The disease is associated with respiratory dis-
orders in piglets and reproductive problems in sows. PRRS
virus (PRRSV), the etiology of PRRS, is a single-stranded
enveloped RNA virus belonging to the order Nidovirales,
family Arteriviridae and genus Arterivirus [2]. Currently,
two types of PRRSV have been reported, the European type
(known as type 1) and the North American type (known as
type 2), with huge genetic variability between and within
each genotype [3, 4].
PRRSV has a narrow cell tropism for cells both in vivo and in
vitro. Differentiated macrophages are the main target cells,
with specific entry mediators determining whether cells are
permissive to PRRSV infection. Up till now, several receptors
such as heparan sulfate, porcine sialoadhesin (pSn), CD163,
CD151, vimentin and DC-SIGN, have been identified as entry
mediators for PRRSV [5–7]. The interaction of heparan sul-
fate with the GP5/M protein complex mediates the binding of
the virus [8]. pSn, also known as porcine sialic acid-binding
immunoglobulin-type lectin-1 (Siglec-1) is associated with
attachment and internalization in a sialic acid-dependent
manner [6, 9]. Porcine CD163 (pCD163) interacts with GP2a
and/or GP4 to mediate disassembly and genome release [10,
11]. pSn and CD163 have been identified as the most import-
ant host receptors that facilitate the infection of PRRSV into
alveolar macrophages [5, 6, 12]. However, recent research has
reported that the expression of Siglec-1 in pigs is not required
for infection with the PRRSV North American strain KS-06
[13]. Meanwhile, research from our laboratory has shown that
different isolates exhibit variable cell tropism. Certain emerg-
ing isolates, such as Lena from Belarus (type 1, subtype 3,
2006, accession number: JF802085), 13V091 (type 1, subtype
1, 2013, accession number: KT159248) from Belgium and
MN-184 from the USA (type 2, 2002, accession number:
DQ176019) have not only shown a strong tropism for
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sialoadhesin-positive macrophages, but also for sialoadhesin-
negative macrophages. This observation suggests that addi-
tional receptors that can replace the role of Siglec-1 as the
receptor enabling PRRSV replication exist [14, 15].
At present, two primary groups of Siglecs have been
identified in humans. One group comprising Siglec-1, CD22
(Siglec-2), myelin-associated glycoprotein (MAG; Siglec-4)
and Siglec-15, are relatively well conserved in mammals. The
other group, known as the CD33-related Siglecs, consists of
CD33 (Siglec-3), Siglec-5 to -13, Siglec-14 and Siglec-16. The
CD33-related group is evolving rapidly and exhibits differen-
ces in composition between mammalian species [16, 17]. In
humans, CD33-related Siglecs interact with several sialylated
pathogens, such as Campylobacter jejuni, Neisseria meningiti-
des, group B streptococcus, Trypanosoma cruzi and human
immunodeficiency virus (HIV) [18, 19]. Siglec-7 has been
reported to interact with the gp120 of HIV-1 and to facilitate
the infection of CD4+ T cells and macrophages [19]. However,
up till now few of the Siglecs have been identified in pigs.
Recently, Siglec-3, Siglec-5 and Siglec-10 were cloned and
characterized in pigs [20–22]. Since Siglec-1 does not seem to
be the only receptor for PRRSV, and the Siglecs reported in
humans are frequently used as receptors for various patho-
gens, we investigated the functions of the already characterized
porcine Siglecs and aimed to identify Siglecs that may have
similar functions to Siglec-1.
RESULTS
Amino acid sequence, structure and expression
analysis of Siglecs
To better understand Siglec-3, Siglec-5 and Siglec-10, their
amino acid sequences were deduced and their structure was
predicted with I-TASSER and by PyMOL V6.6. As expected,
all Siglecs showed a similar structure to Siglec-1, which
includes one V-type and different numbers of C2-type Ig-like
domains, a transmembrane domain and a cytoplasmic tail. As
shown in Fig. 1(a), Siglec-1 has 16 C2-type Ig-like domains,
whereas Siglec-3 has only one C2-type Ig-like domain, and
Siglec-5 and Siglec-10 have three C2-type Ig-like domains.
The V-type Ig domain is indicated in white, the signal peptide
is indicated in yellow and the sialic acid-binding site is indi-
cated in red. The V-type Ig domains of the Siglecs shared a
high amino acid homology, as shown in Fig. 1(c). The con-
served sites are coloured in red. The predicted sialic acid-bind-
ing sites, indicated with a star, were well conserved among
these Siglecs. The sequence of the Siglecs obtained in this
study showed a high amino acid similarity with the Siglec-3
(accession number: AK237787), Siglec-5 (accession number:
AK345769) and Siglec-10 (accession number: AK344974)
sequences reported previously by Alvarez et al. [20] and [22]
(ranging from 99.2–100%) (Fig. 1b).
After the successful construction of the porcine Siglec-3-,
Siglec-5- and Siglec-10-encoding plasmids, the expression of
the Siglecs was examined using immunofluorescence staining
and Western blot. PK-15 cells were transfected with the
Siglec-encoding constructs. Siglec-3, Siglec-5 and Siglec-10
were successfully expressed both in the cytoplasm and at the
surface of the cells (Fig. 2a). To further verify the correct
expression of these Siglecs, a Western blot assay was per-
formed. Based on the amino acid sequence and the size of the
tag, the estimated sizes of Siglec-3, Siglec-5 and Siglec-10
should be approximately 41 kD, 64 kD and 71 kD, respec-
tively. The obtained sizes for Siglec-3, Siglec-5 and Siglec-10
were approximately 60 kD, 120 kD and 95 kD, respectively,
which is larger than the predicted ones (Fig. 2b). To find out if
the discrepancy between the predicted sizes and the observed
sizes was due to post-translational modification(s) such as gly-
cosylation, a deglycosylation assay was performed. Cell lysates
were treated with different glycosidases and analysed by
reducing SDS-PAGE andWestern blot (Fig. 2b). Treatment of
cell lysates with N-glycosidase F (PNGase F), which removes
all types of N-linked glycans, resulted in a single species for
each Siglec, whose size was in accordance with the predicted
size. Treatment with endoglycosidase H (Endo H), which
removes high mannose and some hybrid types of N-linked
carbohydrates, resulted in two species for all Siglecs: a larger
EndoH-resistant form and a smaller EndoH-sensitive form.
This implies that the proteins were partly Golgi-processed and
contained Endo H-resistant complex oligosaccharides. Finally,
cell lysates were treated with Vibrio cholerae sialidase to
remove sialic acids in the a2–3, a2–6 or a2–8 configuration.
Sialidase treatment did not increase the electrophoretic mobil-
ity of the proteins. The results of the sialidase treatments indi-
cated that these proteins carry both high mannose and
complex type N-glycans capped with few or no sialic acids.
Transfected cells expressing Siglec-10 exhibit red
blood-binding capacity in a sialic acid-dependent
manner
The sialic acid-binding capacity of the different Siglecs was
analysed using a red blood cell binding assay. Only Siglec-1-
and Siglec-10-transfected cells showed binding of red blood
cells, as depicted with black arrows in (Fig. 3). Siglec-1-
expressing PK-15 cells that were not treated with sialidase
were still able to bind red blood cells, although to a lesser extent
than cells treated with sialidase. This indicates the existence of
cis-acting sialic acids for both Siglec-1 and Siglec-10 [23].
When red blood cells were treated with sialidase, no binding
was observed for any of these Siglecs (data not shown). In con-
clusion, it can be stated that Siglec-1 and Siglec-10 are sialic
acid-binding lectins that show red blood cell-binding capabil-
ity in a sialic acid-dependent manner [21, 23].
Siglec-10 can increase the infection and production
of PRRSV in a non-permissive cell line in
combination with CD163
To further analyse the function of Siglec-10, the Siglec-
encoding constructs were co-transfected with CD163-
encoding constructs. Forty-eight hours post-transfection,
cells were treated with sialidase or mock-treated and inocu-
lated with PRRSV [Lelystad virus (LV)] or PRRSV MN-184.
Twenty-four hours post-infection, the cells were fixed and
stained for the PRRSV nucleocapsid protein and the super-
natants were collected for virus titration. As shown in Fig. 4
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(a), more virus-positive cells were observed in cells express-
ing Siglec-1 or Siglec-10 in combination with CD163 than
in cells that only expressed CD163. The expression of
Siglec-3 and Siglec-5 in combination with CD163 did not
significantly increase infection compared to cells that only
expressed CD163. Similar results were found for virus titra-
tion. Significantly higher virus production was observed in
cells expressing Siglec-1 and Siglec-10 together with CD163
compared with cells that only expressed CD163 (Fig. 4b).
Neuraminidase treatment of Siglec-1- and Siglec-10-trans-
fected cells significantly increased virus production in the
cells infected with MN-184 and LV compared to the mock-
treated group (P<0.01). Siglec-1 and Siglec-10 also increased
virus production in the untreated cells. This increase was
significant for MN-184 (P<0.01) but not for LV. These
results show that in combination with CD163, Siglec-10 is
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Fig. 1. Amino acid sequence and structure analysis of Siglec-1, Siglec-3, Siglec-5 and Siglec-10. (a) Spatial structure of Siglec-1,3,
Siglec-5 and Siglec-10. Protein structure was predicted by I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) and analysed
by PyMOL (version 6.6). The yellow portion represents the signal peptide; the white portion represents the V-type Ig domain; and the
red dots are the predicted sialic acid-binding site. Different numbers of C-set domains are shown just under the V-type Ig domain. The
surface of the predicted sialic acid-binding sites was expanded and the numbers represent the amino acid position of the predicted
sialic acid-binding sites. (b) Amino acid sequence homology analysis. The homology of the full-length Siglecs obtained in this study
was compared with the sequences that have been reported using MegAlign (DNAstar). Highlighted numbers represent the similarity
between the Siglecs obtained in this study with the reported ones. (c) Amino acid comparison of V-type Ig domain. The V-type Ig amino
acid sequences of Siglec-1, -3, -5 and -10 were compared using CLC sequence viewer (version 6.8.1). The predicted sialic acid-
binding site is indicated with an asterisk.
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able to improve the infection of PRRSV for both LV and
MN-184, and this enhancement is more pronounced
for MN-184. Neuraminidase treatment of the target cells
increased infection considerably.
Human Siglec-10 and other Siglec family members exhibit a
higly conserved predicted sialic acid-binding site. To further
investigate the importance of the Siglec-10 sialic acid-bind-
ing activity, mutagenesis was performed. A mutation of R at
position 119 into E was introduced in the predicted sialic
acid-binding site, which gave rise to a mutant, Siglec-
10R119E. The infection assay with the mutant was performed
in parallel with the non-mutated Siglec-10 as described
above. As shown in Fig. 4(a, c), the mutation resulted in
decreased infection, with a comparable infection rate and
virus production to that seen in the control group
(only expressing CD163). These results provide further
evidence that the sialic acid-binding site in the N-terminal
domain of Siglec-10 is critical for the infection process.
PK-15 cells allow PRRSV attachment and
internalization upon expression of Siglec-10
Previously, it was shown that PK-15 cells allow PRRSV attach-
ment and internalization upon expression of pSn [8, 9]. To
further analyse the specific function of Siglec-10 in the infec-
tion process of PRRSV, a cell line expressing Siglec-10 was
established. Positive cell clones were further identified by IFA
using antibodies against both the V5-tag and Siglec-10. Clones
that were 100% positive against both the V5 tag and Siglec-10
were selected (data not shown). Siglec-10 was present in the
cytoplasm and on the plasma membrane (Fig. 5a). The stably
transfected cell line was used for the binding and internaliza-
tion assay. Upon the incubation of cells with viruses at 4

C,
an abundant number of virus particles were bound to the
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Fig. 2. Expression analysis of Siglec-3, Siglec-5 and Siglec-10 using IFA and Western blotting. (a) PK-15 cells were transfected with
Siglec-3-, Siglec-5- and Siglec-10-encoding vector. Twenty-four hours post-transfection, the cells were fixed with 4% PF and permea-
bilized with Triton X-100 for cytoplasmic staining, or not permeabilized for surface staining. IFA was performed using V5-specific anti-
body (Siglec; green) and Hoechst 33 342 (nuclei; blue). Scale bar: 25 µm (b) Western blot identification. HEK-293T cells were
transfected with Siglec-3, Siglec-5 and Siglec-10. Twenty-four hours post-transfection, the cells were collected and lysed with lysis
buffer. Afterwards, cellular lysates were treated or mock-treated with sialidase, EndoH or PNGase F and analysed by SDS-PAGE and
Western blot. Primary antibody V5-specific mAb (GenScript; A00641) and secondary peroxidase-labelled goat anti-mouse IgG antibod-
ies (Dako) were used for immunoblotting. For the detection of tubulin, an HRP-conjugated anti-alpha tubulin monoclonal antibody
(Abcam; ab40742) was used.
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surface of the cells. Upon incubation at 37

C, large numbers
of virus particles were clustered both on the cell surface and
inside the cytoplasm (Fig. 5b). For normal PK-15 cells, only a
few virus particles could be observed on the surface of cells,
possibly because of the presence of heparan sulfate [8], and no
internalization was observed. To quantify the internalized par-
ticles and with that further prove the critical role of the sialic
acid-binding site, the internalization assay for transient trans-
fected PK-15 and CHO cells expressing wild-type Siglec-10 or
the Siglec-10R119E mutant were analysed and compared. A
clear staining for internalized virus particles was observed in
both cell types (PK-15 and CHO) expressing wild-type Siglec-
10, but for the non-transfected cells or cells expressing Siglec-
10R119E, only a few particles were detected at the plasma
membrane of the cells (Fig. 5c, d). These results show that,
similarly to Siglec-1, Siglec-10 is important for the attachment
and internalization of PRRSV 23].
Distribution of Siglec-10-positive cells in the
porcine spleen
Two areas of the porcine spleen were analysed, the B cell
(CD21+)-rich area and the CD163-positive cell-rich area.
Siglec-10 positive cells were mainly located in the centre of
B cell-rich areas (100% of the CD21-positive cells), but
were also present in CD163+ cell-rich areas (16% of the
CD163+ cells) (Fig. 6). These results show that the majority
of Siglec-10-positive cells in the spleen are B cells, and that a
subset of monocytes that are Siglec-10-positive also exists.
DISCUSSION
Sn and CD163 are two key entry mediators for PRRSV.
However, recent studies in our laboratory demonstrated
that certain virus strains are able to infect Sn-negative cells
[14]. Sn belongs to the Siglec family, containing members
that are commonly used as receptors for various pathogens
[19, 24, 25]. In this study, Siglec-10, a new Sn-like receptor,
was identified as an additional binding and entry receptor
for PRRSV. Siglec-10 was able to mediate the sialic acid-
dependent binding of human erythrocytes and functioned
in a similar way to Siglec-1 during PRRSV infection. How-
ever, clear differences were observed between the two
PRRSV strains LV (type 1) and MN-184 (type 2).
Much Siglec research has been performed in humans. All
Siglecs are type-1 membrane proteins that contain a Sia-
binding, an amino-terminal V-set domain and varying
numbers of C2-set Ig-like domains. As shown in Fig. 1(a),
the predicted structures for porcine Siglec-3, Siglec-5 and
Siglec-10 were quite similar. All of them showed only one
V-set domain followed by 16, 1, 3 and 3 C2-type Ig domains
for Siglec-1, Siglec-3, Siglec-5 and Siglec-10, respectively
(Fig. 1a). The V-set domain and the adjacent C2-set domain
contained a small number of invariant amino acid residues,
including an ‘essential’ arginine on the F b-strand, as indi-
cated in the structure with red dots and marked in the
sequence alignment with an asterisk (Fig. 1a, b). This site
has been predicted to be required for sialic acid binding in
humans. In this study, the estimated binding site of Siglec-
10 was mutated for verification of the sialic acid binding
ability of Siglec-10. The sequences for Siglec-3, Siglec-5 and
Siglec-10 obtained in our study were compared with those
previously characterized by Alvarez and Escalona [20–22].
A high similarity was observed between the sequences,
which demonstrates the high conservation of these Siglecs
among pigs.
Siglecs are cell-surface proteins that bind sialic acids. In this
study, both Siglec-1 and Siglec-10 showed strong red blood
Siglec-1
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Mock-treated
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Siglec-3 Siglec-5 Siglec-10 Mock
Fig. 3. Analysis of the sialic acid-binding capacity of Siglec-1, Siglec-3, Siglec-5 and Siglec-10 by red blood cell binding assay. PK-15
cells that had been transiently transfected with the Siglec-1-, Siglec-3-, Siglec-5- and Siglec-10-encoding vectors were pre-treated
with sialidase or mock-treated and incubated with human erythrocytes. Subsequently, the cells were washed and erythrocyte binding
was evaluated via light microscopy. The black arrows indicate typical sialic acid-dependent erythrocyte binding. Red blood cell binding
was only observed on cells expressing Siglec-1 and Siglec-10.
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Fig. 4. Virus production for the different transfected PK-15 cell groups 24 h after infection. PK-15 cells were transiently transfected
with a pCD163-encoding vector in combination with a Siglec-1, Siglec-3, Siglec-5, Siglec-10 or control vector, and 48 h after transfec-
tion the cells were treated or not treated with sialidase for 1 h and inoculated with PRRSV LV or MN-184 for 1 h. Twenty-four hours
post-infection, the cells were fixed and stained for infection and expression of the different Siglecs and CD163. (a) Immunofluorescence
staining of infected cells with mAb 13E2 (against PRRSV nucleocapsid protein; green) [26, 43] and Hoechst 33 342 (nuclei; blue). The
absolute number of infected cells for each condition was determined and displayed in the images as the mean ± SEM of three indepen-
dent experiments. Scale bar: 50 µm. (b) Expression analysis of the different Siglecs using fluorescence microscopy. PK-15 cells were
fixed, permeabilized and stained with V5-specific mAb (green) and Hoechst 33 342 (nuclei; blue). The absolute number of transfected
cells was determined for each condition and is displayed in the images as the mean ± SEM of three independent experiments. Scale
bar: 50 µm. (c) To evaluate virus production, the cell supernatants collected at 24 h p.i. were titrated and the results are displayed in
the graphs. The CD163/Siglec double-transfected groups that were significantly different from the CD163 single-transfected group are
represented as *P<0.05; **P<0.01 and ***P<0.001.
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cell binding, but only after neuraminidase treatment. Most
Siglecs are masked because of cis-interactions with sialic
acids expressed on the cell surface. Following treatment
with sialidase, Siglecs become unmasked, which allows
them to interact with other ligands [16]. Binding was not
observed in Siglec-3-expressing PK-15 cells even after
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Fig. 5. Porcine Siglec-10 mediates the endocytosis of PRRSV. (a) Immunofluorescence staining of Siglec-10 in stably transfected PK-
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Scale bar: 25 µm. (b) Attachment and internalization of PRRSV in PK-15 S10+ cells. PK-15 expressing Siglec-10 or normal PK-15 cells
were incubated with purified PRRSV LV for 1 h at 4

C or 37

C, allowing binding and internalization, respectively. After washing, the
cells were fixed and stained with Hoechst 33 342 (nuclei; blue) and mAb 13E2 (PRRSV nucleocapsid protein; green), and analysed by
confocal microscopy. Scale bar: 25 µm (c) CHO and PK-15 cells were transiently transfected with wild-type Siglec-10 or the Siglec-
10R119E mutant, and a virus internalization assay was performed 48 h post-transfection. Double staining for Siglec-10/Siglec-10R119E
(red) and co-localized PRRSV particles (13E2; green) was performed and analysed by confocal microscopy. Scale bar: 25 µm. (d) Quan-
tification of PRRSV internalization in CHO and PK-15 cells for three independent experiments.
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treatment, which is in accordance with the studies
by Alvarez and Escalona [20, 21]. For Siglec-5, only a few
cells were detected that bound red blood cells in the three
repeats. This is in contrast with the report from Escalona,
who used purified protein for the porcine red blood cell
binding assay [22]. Several factors might contribute to the
observed differences. Firstly, for the purified protein, more
abundant protein may be present for capturing the red
blood cells, which may account for the higher binding
capacity. Secondly, different production cell types were
used in the two experiments, hence the expression and even
the structure might be different, despite the close similarity
of the sequences. Thirdly, the red blood cells used were dif-
ferent, which might also have contributed to the observed
differences [22].
Previous research showed that sialoadhesin and CD163 join
forces during the entry of PRRSV [7]. Because Siglec-1 is
not necessary for infection with certain PRRSV strains [13,
26], we tried to find other Siglecs (Siglec-3, Siglec-5 and
Siglec-10) that might have the same functionality as Siglec-
1. Infection assays were performed with a non-permissive
cell line that expressed the recombinant receptors. PK-15
cells were transfected with a pCD163-encoding plasmid,
alone or in combination with a Siglec-1, Siglec-3, Siglec-5,
Siglec-10 or Siglec-10R119E mutant-encoding plasmid. After
transfection, cells were treated or mock-treated with siali-
dase and then inoculated with the PRRSV type 1 LV strain
and the PRRSV type 2 MN-184 strain. As it has
previously been shown that MN-184 shows a higher cell tro-
pism for Sn- cells [26], the MN-184 strain was selected for
the present study. The results showed that in addition to
Siglec-1, Siglec-10 significantly increases the infection for
both virus strains, although to a greater extent for MN-184.
Based on the sequence analysis of the amino-terminal V-set
domain, Siglec-10 shares a relatively high similarity with
Siglec-1 [27].
In the present study, a correlation was found between red
blood cell binding and PRRSV binding and infection.
Indeed, the strong red blood cell binding of Siglec-1 and
Siglec-10 coincided with improved PRRSV infection,
whereas the weak red blood cell binding Siglec-5 showed
only a minor increase in PRRSV infection, and the non-red
blood cell binding Siglec-3 did not support PRRSV to any
extent during infection.
PRRSV displays remarkable genetic, antigenic and clinical
variability, resulting in two distinct groups of strains within
the same viral family: type 1 (European type) and type 2
(American type) [3, 28]. Therefore, two strains, one of each
type, were tested for their infectivity. Upon inoculation with
LV, the number of infected cells and the level of virus pro-
duction in cells expressing either Siglec-1 or Siglec-10 in
combination with CD163 were significantly higher than in
cells expressing only CD163 or cells expressing Siglec-3 or
Siglec-5 in combination with CD163. Sialidase treatment of
cells results in the removal of sialic acids on the cell surface,
which allows more abundant binding of sialic acid-carrying
particles such as human red blood cells and PRRSV. The
treatment resulted in higher infection, indicating that
Siglec-10 mediates virus entry in a sialic acid-dependent
manner. With the MN-184 strain, a higher level of infection
was observed compared to LV. Both Siglec-1 and Siglec-10
Fig. 6. Immunofluorescence staining of Siglec-10/CD21 double-positive cells and Siglec-10/CD163 double-positive cells in tissue sec-
tions of the porcine spleen. Immunofluorescence staining of Siglec-10 and CD21 or Siglec-10 and CD163 in tissue sections of the por-
cine spleen. Tissue samples were sectioned (10 µm) and co-immunostained for Siglec-10 (green) and the markers CD21 (red) or
CD163 (red). White dashed lines indicate the border between the B cell-rich area and CD163-rich area. White arrows show CD163+
Siglec-10+ double-positive cells. Scale bar: 25 µm.
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were able to improve the infection rate and virus production
to almost the same level, regardless of sialidase treatment. It
has been stated that the LV strain has a strict cell tropism
for Sn+ macrophages [14, 29], whereas MN-184 and some
other type 2 PRRSV strains are able to infect Sn  cells [26].
In addition to Sn, these viruses most likely use another
binding and entry receptor. Meanwhile, the most recent
report from Yuste et al. [30] showed that PRRSV is able to
replicate efficiently in splenic CD163+ macrophages that
express low levels of Siglec-1 but high levels of Siglec-3 and
Siglec-5. However, Siglec-3 and Siglec-5 did not seem to
play a role in infection, which further confirmed our results
showing that the non-permissive cell line expressing Siglec-
3 or Siglec-5 in combination with CD163 did not improve
virus infection and production. The results of the present
study suggest that Siglec-10 might be a new receptor candi-
date for PRRSV binding/internalization, especially for type
2 viruses.
As mentioned earlier, an ‘essential’ arginine residue in all
the known Siglecs is important for binding Sia-containing
ligands. To further elucidate the function of Siglec-10, a
site-directed mutation was performed. The predicted sialic
acid-binding site aa 119 in the V-set domain was mutated
from R to E. This resulted in a loss of human red blood cell
binding activity and the absence of increased virus produc-
tion. These results provide further evidence showing that
the N terminal sialic acid-binding site is essential for virus
infection, which is similar to Siglec-1 [31, 32]. Since siaload-
hesin requires the sialic acid-binding activity to mediate the
attachment of PRRSV [32], and given the observations
above, we speculated that Siglec-10 might have a similar
function during virus infection. A cell line expressing Siglec-
10 was established and the virus binding and internalization
assay was performed. The results showed that Siglec-10 was
able to bind and internalize virus particles. In contrast, the
cells expressing mutant Siglec-10R119E were unable to bind
and internalize the virus. Together, these results support the
hypothesis that the sialic acid-binding site in the N terminal
of Siglec-10 is crucial for virus binding and internalization
(Fig. 5).
A previous study by Escalona et al. [21] showed that Siglec-
10 was mainly expressed on B cells and also showed weak
expression on monocytes. To check for the presence of
splenic CD163+ macrophages expressing Siglec-10, double
stainings for CD21/Siglec-10 and CD163/Siglec-10 were
performed in the spleen. As was shown in the results, in the
B cell-rich centre almost 100% of the Siglec-10-positive cells
were found to be CD21-positive, confirming the results
from the work by Escalona et al. [21], in which it was seen
that Siglec-10 is mainly expressed on B cells. Furthermore,
in the CD163-positive area around 16% of the CD163-posi-
tive cells co-expressed Siglec-10 (Fig. 6). Inconsistent
reports exist regarding the expression of Siglec-10 in
humans. Munday et al. [27] reported low levels of Siglec-10
expression on human CD19+ B lymphocytes and monocytes
for a small subset of CD16+ CD56- NK cells, and even lower
levels on eosinophils. In contrast, Whitney et al. [33]
reported no expression on B cells, whereas the granulocytes
were Siglec-10-positive in humans [33]. The reactivity of
the antibody used and the presence of different splicing var-
iants of Siglec-10 might account for this variation. Based on
the present study and a previous study by Escalona et al.
[21], it can be stated that in pigs porcine Siglec-10 is mainly
expressed on B cells and also on a minor subset of mono-
cytes. The minor subset of monocytes may be an important
new replication target for PRRSV in vivo. In addition, B-
cells can be expected to act as a carrier for the virus in vivo,
given that Siglec-10 is able to bind and internalize PRRSV
particles. The absence of CD163 in B cells hampers PRRSV
in infecting these cells. Siglec-10/-G has also been reported
to be an inhibitory receptor on B cells [34–36]. Inhibitory
receptors are known to influence various functions of
immune cells, such as the regulation of cellular signalling,
cell-to-cell interactions and endocytosis through an ITIM
motif [16]. The sequence of porcine Siglec-10 contains one
ITIM and one ITIM-like motif. When ITIM-possessing
inhibitory receptors interact with their ligand, their ITIM
motif becomes phosphorylated, allowing them to recruit
other enzymes, such as SHP-1 and SHP-2. These kinds of
phosphatases will decrease the activation of the molecules
involved in cell signalling [37], which can negatively regu-
late signal transduction [38]. Human Siglec-10 is reported
to be associated with the tyrosine phosphatase SHP-1, a
known negative regulator of nuclear factor kB (NF-kB) acti-
vation [39], while the inhibition of NF-kB activation is
mediated by SHP-1 via the ITIM motif of Siglec-10 [33].
NF-kB belongs to a family of inducible transcription factors
that are involved in pathogen- or cytokine-induced immune
and inflammatory responses, as well as cell proliferation
and survival [40]. One of the most remarkable features of
PRRSV infection is the failure to elicit the expression of
inflammatory cytokines in the lungs of pigs, particularly
type I interferons, interleukin-1 (IL-1) and tumour necrosis
factor alpha (TNF-a), which are important in antiviral
responses. Whether this phenomenon is related to the func-
tion of Siglec-10 needs to be identified [41, 42]. In our
study, in addition to its binding and internalization ability,
there is a possibility that Siglec-10 also acts as an inhibitory
immune receptor to facilitate the infection of PRRSV. Fur-
ther studies are needed to test the hypothesis that PRRSV
can interact with Siglec-10 via the ITIM motif on B cells,
leading to downregulation of immune-related signal trans-
duction, and therefore possibly escape the immune system.
In conclusion, this study revealed that, similarly to Siglec-1,
Siglec-10 is able to improve PRRSV infection in non-per-
missive cells in combination with CD163. Like Siglec-1,
Siglec-10 is able to mediate the attachment and endocytosis
of PRRSV, which is dependent on the sialic acid-binding
activity of the N-terminal immunoglobulin domain. Siglec-
10 showed a higher affinity towards the type 2 PRRSV strain
MN-184compared to the type 1 PRRSV strain LV. For the
type 2 PRRSV strain MN-184, Siglec-10 was as performant
as Siglec-1 in its receptor function, whereas for the type 1
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PRRSV strain LV, Siglec-1 was the most effective entry
mediator. In the future, more work will be required to deter-
mine the replication kinetics of other PRRSV strains in
Siglec-10-positive cells, and the impact of PRRSV replica-
tion in these cells on the immune response.
METHODS
Cell lines, viruses and antibodies
PK-15 (porcine kidney) cells were grown in MEM supple-
mented with 10% foetal bovine serum (FBS) and a mixture
of antibiotics. Marc-145 cells were cultivated as described
previously [7]. They were then maintained in a humidified
5% CO2 atmosphere at 37

C. The European prototype
PRRSV LV strain was passaged 13 times on macrophages
and subsequently 5 times on Marc-145 cells. The MN-184
virus strain (American type) was passaged five times on
Marc-145 cells.
PRRS virions were visualized via the nucleocapsid protein
specific mAb 13E2 [26, 43] and a secondary conjugate. For
detection of the V5-tag, a mouse monoclonal antibody
(GenScript; A00641) and a goat anti-mouse IgG horseradish
peroxidase (HRP)-labelled secondary antibody (Dako;
P0447) were used, or a directly labelled mAb conjugated
with FITC (Invitrogen; R963-25), was used. For the visuali-
zation of CD163, either a mouse monoclonal antibody
(2A10/11, IgG1; AbD Serotec, Dusseldorf, Germany) or a
goat polyclonal antibody (R and D Systems, Minneapolis)
with appropriate secondary conjugates were used.
Cloning, construction and identification of porcine
Siglecs
The primer pairs were designed based on the sequences sub-
mitted and characterized on NCBI (Table 1). The coding
region of putative porcine Siglecs were amplified and
cloned. Briefly, total RNA was extracted from porcine
spleen (Siglec-10) or PBMCs (Siglec-3 and Siglec-5)
using the RNeasy mini kit (Qiagen). Afterwards, reverse-
transcription PCR (RT-PCR) was performed using random
primers with the SuperScript III reverse transcriptase kit
according to the standard procedure (Thermo Science).
After RT-PCR amplification with the Herculase DNA
polymerase kit (Agilent Technologies), the purified PCR
product was cloned into the pCDNA3.1D/V5-His-TOPO
vector in frame with the V5 tag (Invitrogen) via restriction
enzymes and T4 ligase (Invitrogen). Constructs were veri-
fied by sequencing. Porcine sialoadhesin and CD163 were
previously cloned into the pcDNA3.1D/V5-His-TOPO vec-
tor (Invitrogen) and the pBudCE4.1 vector (Invitrogen) [7,
9]. The spatial structure of the Siglecs was predicted
using the I-TASSER online tool (https://zhanglab.ccmb.
med.umich.edu) and analysed by PyMOL (version 6.6).
Comparisons of the predicted domains, motifs and features
of Siglecs from different species were performed on the
Sample Modular Architecture Research Tool (SMART). For
further functional analysis of Siglec-10, a point-mutation
(R119E) was introduced into the predicted sialic acid-bind-
ing domain of Siglec-10 with the primers pS10RE-FW and
pS10RE-RV, as listed in Table 1. Site-directed mutagenesis
was carried out using the Quick-change site-directed muta-
genesis kit (Agilent Technologies) according to the manu-
facturer’s instructions.
Expression analysis of Siglecs in eukaryotic cells
by immunofluorescence analysis and Western blot
PK-15 cells were transiently transfected with the Siglec-
encoding vectors using Lipofectamine (Invitrogen)
following the manufacturer’s instructions. Forty-eight hour
post-transfection, the cells were fixed with 4% paraformal-
dehyde, permeabilized with 0.01% Triton X-100 or not per-
meabilized, and stained with Hoechst (10 µgml 1;
Invitrogen) and directly labelled V5-FITC mAbs (1 : 500,
Invitrogen; R963-25). The results were analysed by (confo-
cal) fluorescence microscopy (Leica Microsystems GmbH,
Heidelberg, Germany).
For Western blot analysis 48 h post-transfection, cells
were collected and washed using ice-cold phosphate-buff-
ered saline (PBS). Cellular lysates were prepared by lysis
in buffer containing 50mM Tris (pH 7.4), 150mM NaCl,
1% Nonidet P-40, 0, 1% SDS, 5mM EDTA and protease
inhibitor cocktail (Roche) in water. Samples were either
left untreated, or treated with endoglycosidase H, PNGase
F (New England Biolabs, Inc.) or 100 mU/ml Vibrio chol-
erae sialidase (Roche Applied Science) for 3 h at 37

C.
Table 1. The list of primers used in the study
Primers used for PCR amplification of Siglec-3, -5 and -10 and for the mutagenesis of Siglec-10, artificial restriction sites (underlined) for cloning,
mutated residues (bold)
Name Primer Sequence Fragment size Purpose
Siglec3-FL-F 5¢ -GTTAAGCTTaGCCACCATGCGGCCGCTGCTGCTGCT-3¢ 1143 bp Full-length cloning of Siglec-3
Siglec3-FL-R 5¢-TCTtCTCGAGttCCGGGTCCCGATCTCTGTGTAT-3¢
Siglec5-FL-F 5¢-GTTAAGCTTGCCACCATGGTGCCCCTGCTGCTGCTGCTG-3¢ 1665 bp Full-length cloning of Siglec-5
Siglec5-FL-R 5¢-TCTCTCGAGttTTTGCTTTTTCTGATCTCTGAGTAC-3¢
Siglec10-FL-F 5¢-CTTGGTACCGCCACCATGCTCCTGCCGCTGCTCTTAG-3¢ 1842 bp Full-length cloning of Siglec-10
Siglec10-FL-R 5¢-GCTGCGGCCGCTGTGGAACTGGACCGCAGCATATT-3¢
pS10R119E-FW 5¢-CATGCCGCCTACTTCTTTgaaTTGGAGAGAGGCCCTTAC-3¢ 1842 bp Mutation of binding site for Siglec-10
pS10R119E-RV 5¢-GTACGGCGGATGAAGAAActtAACCTCTCTCCGGGAATG-3¢
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Afterwards, samples were mixed with reducing Laemli
buffer (5) SDS-PAGE loading dye, boiled for 10min,
and subjected to SDS-PAGE (12% gel) using a BioRad
Mini Protean 3 system. Proteins were transferred to a
PVDF membrane (Membrane Hybond-P; GE Healthcare)
using a BioRad mini trans-blot system, and then
the membranes were blocked overnight using blocking
solution (5% skimmed milk in PBS, 0.1% Tween-20). A
V5-specific mAb (GenScript; A00641) diluted 1 : 2000 in
PBS and peroxidase-labelled goat anti-mouse IgG anti-
bodies (Dako) diluted 1 : 1000 in blocking solution were
used for the detection of protein. HRP-conjugated anti-
alpha tubulin monoclonal antibody (Abcam, ab40742)
was used to stain tubulin. The results were visualized
with an ECL Western blotting detection system (GE
Healthcare).
Red blood cell binding assay
Human red blood cells were obtained from healthy donors
and stored at 4

C in Alsever’s solution. After three wash-
ings, cells were diluted in RPMI. PK-15 cells were tran-
siently transfected with the Siglec-encoding vectors using
Lipofectamine (Invitrogen). Forty-eight hours post transfec-
tion, cells were washed with RPMI and half of the wells
were pre-treated with 10 mU/ml Vibrio cholerae sialidase
(Roche) in RPMI for 1 h at 37

C. The other half were
mock-treated with RPMI. After treatment, cells were
washed three times with RPMI and incubated with washed
erythrocytes (0.25% v/v in RPMI) for 1 h at 37

C. Subse-
quently, cells were washed and erythrocyte binding was
evaluated by light microscopy.
Infection experiments on non-target cells
expressing recombinant receptors with or without
neuraminidase treatment
PK-15 cells were transiently transfected with a pCD163-
encoding vector alone (pCD163+) or in combination with a
Siglec-encoding vector (pCD163+ Siglec+). Forty-eight hours
post-transfection, cells were washed and pre-treated with 10
mU/ml Vibrio cholerae sialidase (Roche) in RPMI or just
mock-treated with RPMI for 1 h at 37

C. After three washes
with PBS, cells were inoculated with 250 µl PRRSV LV or
MN-184 virus at a m.o.i. of 0.5. At 1 h p.i., the inoculum
was removed, cells were washed three times with PBS and
washing fluids were replaced with 300 µl MEM containing
10% FCS. At 24 h p.i., cell supernatants were collected and
cells were fixed with ice-cold methanol. For the quantifica-
tion of infected cells, fixed cells were incubated with the
PRRSV N-specific monoclonal antibody 13E2 (IgG2a) fol-
lowed by a secondary goat anti-mouse IgG2a FITC-labelled
antibody (Invitrogen) [43]. To reduce the background sig-
nal, 10% negative goat serum was included for blocking
during each step. Cell nuclei were stained with Hoechst
(10 µgml 1, Invitrogen) for 10min at room temperature.
The infection level and expression of the different Siglecs
and pCD163 were quantified by confocal microscopy (abso-
lute number of virus- or receptor-positive cells). To deter-
mine the titre of extracellular virus, the collected
supernatant was centrifuged to remove cell debris and used
for virus titration. For titration on Marc-145 cells, cells were
seeded 3 days before inoculation. Monolayers were inocu-
lated with a 10-fold dilution series of the samples and incu-
bated for 7 days at 37

C. The cytopathic effect (CPE) was
then visualized by light microscopy. Finally, the virus titres
were calculated as TCID50 ml
 1[44]. Parallel experiments
were performed for the binding site-directed mutation
construct.
PK-15
S10+
cell line establishment, virus binding
and internalization analysis
PK15 cells were transfected with the Siglec-10-encoding
plasmid containing the geneticin resistance gene using Lipo-
fectamine (Invitrogen). The Siglec-10-expressing PK15 cells
were selected with geneticin (200 µgml 1, GIBCO) and sub-
sequently subcloned. Cells were initially identified using
immunofluorescence staining, primarily using V5-FITC
mAbs (Invitrogen; R963-25) and further confirmed using
a monoclonal antibody (1G10) against Siglec-10 that was
developed in this study. To stain the PK-15S10+ cells, cells
were fixed with 4% PF and permeabilized or not permeabi-
lized with 0.1% Triton X-100 for cytoplasmic staining or
surface staining, respectively. Next, cells were incubated
with 1G10 (IgG1) diluted in PBS containing 10% NGS, fol-
lowed by an incubation with secondary goat anti-mouse
IgG1 FITC-labelled antibody. MAb 13D12 was used as an
isotype-matched irrelevant control [45]. Cell nuclei were
stained with Hoechst for 10min at room temperature. The
established cell line was used for the virus binding and inter-
nalization assay. For virus binding, cells were inoculated
with purified LV virus at 4

C for 1 h. Then, cells were fixed
with 4% paraformaldehyde. For internalization, the cells
were fixed with 4% paraformaldehyde 1 h post-virus inocu-
lation. After fixation, cells were washed with PBS and per-
meabilized with a 0.1% Triton X-100 solution in PBS. As a
control, non-transfected cells were also fixed after inocula-
tion of the virus, and subsequently washed and permeabi-
lized. Cells were stained for PRRSV particles using 13E2
specific to PRRSV N protein [43] and goat anti-mouse
FITC antibody. The antibody 1C11 against gB of PrV
(IgG2a) was used as an irrelevant isotype control [45].
The results were analysed by confocal microscopy (Leica
Microsystems GmbH).
For quantification of the internalized virus particles for cells
expressing Siglec-10, PK-15 and CHO cells were transiently
transfected with Siglec-10 and Siglec-10R119E mutant
expressing plasmid with Lipofectamine. Cells were inocu-
lated with purified PRRSV LV at a m.o.i. of 5, and after
incubation for 1 h at 37

C, cells were washed and fixed with
methanol. Virus particles were stained using PRRSV nucle-
ocapsid-specific mAb 13E2 (IgG 2a), and Siglec-10 was
stained using 1G10 (1 : 10, IgG1). The antibodies 13D12
against gD of PRV (IgG1) and 1C11 against gB of PrV
(IgG2a) were used as irrelevant isotype controls [45]. Co-
localization of Siglec-10 with virus particles was counted
(15 cells for each experimental condition).
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Monoclonal antibody production
Five 4–6week-old Balb/c mice were immunized intramus-
cularly with 2 µg of recombinant Siglec-10-encoding
eukaryotic expression plasmid and boosted 2 and 4 weeks
later with the same amount. After four immunizations, all
of the mice had seroconverted. Serum was collected from
immunized mice and used as a source of polyclonal anti-
bodies. The mouse with the highest antibody titre was
selected for a final boost with PK-15S10+ cells. Four days
later, spleen lymphocytes were fused with the SP2/0 mye-
loma cells as described previously [43, 46], using polyethyl-
ene glycol 4000 (Sigma). Siglec-10-specific hybridomas were
screened by performing a cell-based IPMA with the hybrid-
oma supernatant. Briefly, PK-15S10+ cells were fixed by dry-
ing and subsequent incubation with 4% paraformaldehyde
and methanol +1% H2O2. Next, cells were incubated with
undiluted hybridoma supernatant for 1 h at 37

C, followed
by biotinylated anti-mouse IgG antibody and streptavidin-
biotinylated HRP complex (GE healthcare). Afterwards,
AEC substrate was added and the results were analysed by
light microscopy. Positive hybridomas were subcloned by
limiting dilution. The isotype of the obtained mAb was
determined by ELISA with a mouse monoclonal antibody
isotyping test kit from Zymed Laboratories, Inc.
Immunoﬂuorescence staining analysis for Siglec-
10 in porcine spleen tissue sections
To identify Siglec-10-positive cells in tissues, 10 µm thick
cryosections of frozen porcine spleen tissues were made
and fixed in 100% methanol at  20

C for 15min. Porcine
spleen tissues were collected from three conventional pigs.
For double staining of B cells and Siglec-10 positive cells,
primary mouse monoclonal antibodies against the B cell
marker CD21 (IgG2b) and Siglec-10 (1G10, IgG1) and iso-
type-specific secondary antibodies conjugated with FITC or
Alexa Fluor 594 (Invitrogen) were used. Cell nuclei were
stained with Hoechst 33 342. For the staining of CD163 and
Siglec-10 double-positive cells, goat polyclonal antibody
against CD163 (R and D Systems, Minneapolis) and mouse
polyclonal antibody against Siglec-10 were incubated at 4

C
overnight. After three washes with PBS, sections were incu-
bated with rabbit anti-goat AF594 for 1 h at 37

C. Then, the
sections were blocked with negative rabbit serum for 30min
and incubated with goat anti-mouse biotin-labelled second-
ary antibody, followed by streptavidin FITC-labelled anti-
body. For the staining with biotin-labelled antibody, the
tissues were pre-treated with an avidin/biotin blocking kit
(Thermo Fisher). Counting was performed in 3 cryosections
for each pig, with 10 fields per cryosection, selected in a ran-
dom way. Results were analysed using a Leica TCS SPE
laser-scanning confocal microscope (Leica Microsystems
GmbH). Positive cells were counted within regions of inter-
est (ROIs), including the B cell-rich area and the CD163-
rich area, and calculated using Image J.
Statistical analysis
All experiments were performed three times. Statistical sig-
nificance (*P<0.05; **P<0.01; ***P<0.001) was calculated
using the two-way ANOVA test followed by the Bonferroni
post-test to determine the differences between the different
receptor-transfected groups and the control group, and also
the treated and untreated groups. All of the statistical analy-
ses were performed using Graphpad Prism 5.
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